Amphista Therapeutics
PrivateLast Round
Series B
Extension
Dec 13, 2022
Total Funding Raised
$60.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Amphista Therapeutics is a biotechnology company that develops next-generation targeted protein degradation therapeutics for the treatment of cancer and other severe diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amphista Therapeutics Comparables
Compare Amphista Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 89% | |
| Pin Therapeutics | 84% | |
| Dunad Therapeutics | 84% |
Amphista Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 13, 2022 | ||||
| Series B | Mar 17, 2021 | ||||
| Series A | Apr 7, 2020 | ||||
| Seed | Dec 20, 2017 |
Key People
Founding team and executive leadership
Amphista Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| BioMotiv | Series B, Series A |
| Forbion | Series B |
| Advent Life Sciences | Series B, Seed, Series B Extension, Series A |
| European Investment Fund | Seed, Series A |
| Gilde Healthcare | Series B |
| Scottish Investment Bank (Scottish Enterprise) | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 77% MoM.
- Jul 25, 2026
Monthly visitors increased 51% MoM.
Amphista Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Amphista Therapeutics's valuation, stock price, and market status.
Is Amphista Therapeutics a public or private company?
Amphista Therapeutics is a private company.
What is the current stock price of Amphista Therapeutics?
Amphista Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Amphista Therapeutics worth (valuation)?
Valuation information for Amphista Therapeutics is not publicly available.
Can I buy Amphista Therapeutics stock?
Amphista Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Amphista Therapeutics's last funding round?
Amphista Therapeutics's most recent funding round was Series B Extension on December 13, 2022.
Who are the main investors in Amphista Therapeutics?
Key investors in Amphista Therapeutics include Forbion Capital Partners, Advent Life Sciences, Gilde Healthcare.
Will Amphista Therapeutics IPO soon?
No public IPO plans have been announced for Amphista Therapeutics.
How can I track Amphista Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amphista Therapeutics's secondary market activity and sign up for updates.